Alexandre Martins Do Nascimento
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexandre Martins Do Nascimento has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Deborah Schechtman
University of São Paulo
5 shared publications - Ana Maria Rodrigues
Department of Biochemistry, Chemistry Institute, University of São Paulo, São Paulo, Brazil
3 shared publications - Camila Squarzoni Dale
Department of Anatomy, Institute of Biomedical Sciences University of Sao Paulo Sao Paulo Brazil
3 shared publications - Beatriz C. Moraes
Department of Dermatology, University of California San Francisco, San Francisco, CA, USA
2 shared publications - Raphael de Siqueira Santos
Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brazil
2 shared publications - Allan Pradelli Roldão
Department of Biochemistry, Chemistry Institute, University of São Paulo, SP 05508-000, Brazil
1 shared publication
Latest Publications
- Open Access
- 25 May 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (10) , 2365-2378
Placebo Effect in Levodopa‐Induced Dyskinesia: A Systematic Review and Meta‐Analysis
Background: Levodopa‐induced dyskinesia (LID) is a complication of Parkinson's disease (PD) treatment. While the placebo effect is a known component in PD clinical trials, its specific magnitude in the context of LID is not well characterized. Objective: To quantify the magnitude of the placebo response in LID trials and to identify potential moderators of this effect. Methods: We conducted a systematic review and meta‐analysis of double‐blind, placebo‐controlled trials in patients with PD and LID. The primary outcome was the change in dyskinesia severity in the placebo arm, pooled using random‐effects model. Results: Thirty one publications, comprising 1329 patients, were included. Data were stratified by reporting methodology: 16 studies provided primary LS mean change data, 11 provided simple change and the remaining studies contributing solely to subgroup analyses. The primary meta‐analysis, revealed a statistically significant placebo response of moderate magnitude (pooled SMD = −0.48, p < 0.0001), with significant heterogeneity ( I 2 = 47.6%). Subgroup analyses showed this corresponded to clinically measurable improvements, including a mean reduction of −6.78 points on the UDysRS and an increase of +1.27 h in “Good On Time.” Meta‐regression identified that a larger placebo effect was significantly associated with older patient age ( p = 0.014), a higher proportion of female participants ( p = 0.016), and shorter study duration ( p = 0.006). Conclusion: The placebo response in LID is a consistent, clinically relevant phenomenon modulated by patient demographics and trial duration. Quantifying this response is essential for design and accurate interpretation of future trials.
- 25 May 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (10) , 2365-2378
Open AccessPlacebo Effect in Levodopa‐Induced Dyskinesia: A Systematic Review and Meta‐Analysis
Background: Levodopa‐induced dyskinesia (LID) is a complication of Parkinson's disease (PD) treatment. While the placebo effect is a known component in PD clinical trials, its specific magnitude in the context of LID is not well characterized. Objective: To quantify the magnitude of the placebo response in LID trials and to identify potential moderators of this effect. Methods: We conducted a systematic review and meta‐analysis of double‐blind, placebo‐controlled trials in patients with PD and LID. The primary outcome was the change in dyskinesia severity in the placebo arm, pooled using random‐effects model. Results: Thirty one publications, comprising 1329 patients, were included. Data were stratified by reporting methodology: 16 studies provided primary LS mean change data, 11 provided simple change and the remaining studies contributing solely to subgroup analyses. The primary meta‐analysis, revealed a statistically significant placebo response of moderate magnitude (pooled SMD = −0.48, p < 0.0001), with significant heterogeneity ( I 2 = 47.6%). Subgroup analyses showed this corresponded to clinically measurable improvements, including a mean reduction of −6.78 points on the UDysRS and an increase of +1.27 h in “Good On Time.” Meta‐regression identified that a larger placebo effect was significantly associated with older patient age ( p = 0.014), a higher proportion of female participants ( p = 0.016), and shorter study duration ( p = 0.006). Conclusion: The placebo response in LID is a consistent, clinically relevant phenomenon modulated by patient demographics and trial duration. Quantifying this response is essential for design and accurate interpretation of future trials.
- Open Access
Subtype-Resolved Pain-Signaling Architectures Reveal Conserved Drug-Target Interaction Networks in DRG Nociceptors
Pain management has been challenging and a major obstacle lies in the limited translational success between preclinical studies, often based on rodent models and evoked nociception behavioral assays, whose validity is often questioned. The dorsal root ganglia (DRG) contains diverse nociceptor subtypes that serve as the primary afferent pathways for detecting painful stimuli and analgesics often target proteins expressed in nociceptors. This makes the distinct protein repertoires and molecular interactors within nociceptor subtypes a key focus for understanding which molecular players drive pain processing and how they may be therapeutically targeted. The confirmation of cross-species conservation of pain-related signaling pathways, mediated by nociceptors, could help to elucidate the molecular mechanisms by which the drugs act across species. In this context, we constructed and compared experimentally-validated protein-protein interaction (PPI) networks based on drug targets and their direct binding partners for nociceptor subtypes supported by single-nuclei transcriptome data from mouse and human DRGs. We found that overall gene expression is more conserved across mice than in human nociceptor subtypes, indicating a higher degree of molecular specialization of human nociceptors. Overall signaling network analyses revealed subtype- and species-specific conservation related to pain signaling, with some particularities, in which key drug targets mediate broader cellular processes beyond pain signaling and neuronal depolarization. Altogether, this resource may help to further understand the molecular mechanisms of specific drug targeting, and the proposed workflow can be used to identify and prioritize pain-related pathways in the DRG, advancing target identification and translational medicine.
Open AccessSubtype-Resolved Pain-Signaling Architectures Reveal Conserved Drug-Target Interaction Networks in DRG Nociceptors
Pain management has been challenging and a major obstacle lies in the limited translational success between preclinical studies, often based on rodent models and evoked nociception behavioral assays, whose validity is often questioned. The dorsal root ganglia (DRG) contains diverse nociceptor subtypes that serve as the primary afferent pathways for detecting painful stimuli and analgesics often target proteins expressed in nociceptors. This makes the distinct protein repertoires and molecular interactors within nociceptor subtypes a key focus for understanding which molecular players drive pain processing and how they may be therapeutically targeted. The confirmation of cross-species conservation of pain-related signaling pathways, mediated by nociceptors, could help to elucidate the molecular mechanisms by which the drugs act across species. In this context, we constructed and compared experimentally-validated protein-protein interaction (PPI) networks based on drug targets and their direct binding partners for nociceptor subtypes supported by single-nuclei transcriptome data from mouse and human DRGs. We found that overall gene expression is more conserved across mice than in human nociceptor subtypes, indicating a higher degree of molecular specialization of human nociceptors. Overall signaling network analyses revealed subtype- and species-specific conservation related to pain signaling, with some particularities, in which key drug targets mediate broader cellular processes beyond pain signaling and neuronal depolarization. Altogether, this resource may help to further understand the molecular mechanisms of specific drug targeting, and the proposed workflow can be used to identify and prioritize pain-related pathways in the DRG, advancing target identification and translational medicine.
- Open Access
Temporal regulation of TRP channels during partial sciatic nerve ligation is modulated by PLC□ in male mice
Neuropathic pain is a debilitating condition afflicting millions worldwide, still lacking a proper and effective treatment. Understanding the underlying mechanisms that lead to neuropathic pain may lead to the discovery of new targets. Previously, we found that PLC□ is a key player in mechanical hypersensitivity triggered by either capsaicin or complete Freund’s adjuvant induced inflammation. Here, we investigated the role of PLCγ in neuropathic pain using a partial sciatic nerve ligation (PSNL) injury model in male mice and a peptide inhibitor of PLCγ activation (TAT-pQYP) injected at different time points after injury. Mechanical hypersensitivity was reversed by TAT-pQYP at 7, 14, and 28 days post-injury (dpi). Furthermore, both TAT-pQYP and the TRPA1 inhibitor HC-030031, but not the TRPV1 inhibitor capsazepine, were able to reverse mechanical hypersensitivity at 14 dpi. In contrast, all three treatments significantly improved the mechanical threshold at 28 dpi. After a challenge with TRPV1 agonist capsaicin at 14 dpi, TAT-pQYP treated animals exhibited increased sensitivity. We also found decreased TRPV1 mRNA levels in the DRG of PSNL animals at 14 dpi that returned to baseline at 28 dpi. TAT-pQYP treatment normalized TRPV1 expression to sham levels at 14 days. Conversely, TRPA1 mRNA expression increased at 14 days and returned to baseline at 28 days, while TAT-pQYP reduced TRPA1 expression at 14 days. At this same time point, injection of a pan-PLC (U73122), or Trk (GNF-5837) inhibitor reduced mechanical hypersensitivity and decreased Trpa1 expression, whereas only PLC□ inhibition by TAT-pQYP or Trk inhibition restored Trpv1 levels to Sham values. These findings indicate that PLCγ, and Trk signaling are important for expression of Trpa1 and activity of Trpv1 . Taken together, our results show that dynamic changes in Trpv1 expression in the PSNL model account for differential sensitivity to TRPV1 inhibition and suggest that clinically relevant pharmacological inhibitors targeting ion channels may vary in efficacy depending on the temporal regulation of expression during neuropathic pain development. Finally, we show that TAT-pQYP is able to reverse mechanical hypersensitivity arising from neuropathic pain, adding evidence that PLCγ is a promising target to be explored for neuropathic pain management. Significance statement: We show that the efficacy of inhibiting TRPV1 or TRPA1 on neuropathic pain in a partial sciatic nerve ligation model and that pain mitigation depends on the dynamic changes of channel expression post-injury, in the dorsal root ganglion, emphasizing that temporal regulation of drug targets should be taken into account when choosing therapeutic strategies for pain treatment. Notably, we identify PLCγ as a promising therapeutic target, as its inhibition with TAT-pQYP reverses mechanical hypersensitivity during different stages of injury progression by modulating expression and activity of TRP channels.
Open AccessTemporal regulation of TRP channels during partial sciatic nerve ligation is modulated by PLC□ in male mice
Neuropathic pain is a debilitating condition afflicting millions worldwide, still lacking a proper and effective treatment. Understanding the underlying mechanisms that lead to neuropathic pain may lead to the discovery of new targets. Previously, we found that PLC□ is a key player in mechanical hypersensitivity triggered by either capsaicin or complete Freund’s adjuvant induced inflammation. Here, we investigated the role of PLCγ in neuropathic pain using a partial sciatic nerve ligation (PSNL) injury model in male mice and a peptide inhibitor of PLCγ activation (TAT-pQYP) injected at different time points after injury. Mechanical hypersensitivity was reversed by TAT-pQYP at 7, 14, and 28 days post-injury (dpi). Furthermore, both TAT-pQYP and the TRPA1 inhibitor HC-030031, but not the TRPV1 inhibitor capsazepine, were able to reverse mechanical hypersensitivity at 14 dpi. In contrast, all three treatments significantly improved the mechanical threshold at 28 dpi. After a challenge with TRPV1 agonist capsaicin at 14 dpi, TAT-pQYP treated animals exhibited increased sensitivity. We also found decreased TRPV1 mRNA levels in the DRG of PSNL animals at 14 dpi that returned to baseline at 28 dpi. TAT-pQYP treatment normalized TRPV1 expression to sham levels at 14 days. Conversely, TRPA1 mRNA expression increased at 14 days and returned to baseline at 28 days, while TAT-pQYP reduced TRPA1 expression at 14 days. At this same time point, injection of a pan-PLC (U73122), or Trk (GNF-5837) inhibitor reduced mechanical hypersensitivity and decreased Trpa1 expression, whereas only PLC□ inhibition by TAT-pQYP or Trk inhibition restored Trpv1 levels to Sham values. These findings indicate that PLCγ, and Trk signaling are important for expression of Trpa1 and activity of Trpv1 . Taken together, our results show that dynamic changes in Trpv1 expression in the PSNL model account for differential sensitivity to TRPV1 inhibition and suggest that clinically relevant pharmacological inhibitors targeting ion channels may vary in efficacy depending on the temporal regulation of expression during neuropathic pain development. Finally, we show that TAT-pQYP is able to reverse mechanical hypersensitivity arising from neuropathic pain, adding evidence that PLCγ is a promising target to be explored for neuropathic pain management. Significance statement: We show that the efficacy of inhibiting TRPV1 or TRPA1 on neuropathic pain in a partial sciatic nerve ligation model and that pain mitigation depends on the dynamic changes of channel expression post-injury, in the dorsal root ganglion, emphasizing that temporal regulation of drug targets should be taken into account when choosing therapeutic strategies for pain treatment. Notably, we identify PLCγ as a promising therapeutic target, as its inhibition with TAT-pQYP reverses mechanical hypersensitivity during different stages of injury progression by modulating expression and activity of TRP channels.
- 1 September 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 329 (3) , C821-C833
PLCγ has a dual role in capsaicin-triggered neurogenic inflammation promoting mechanical hypersensitivity and edema in male mice
When activated, TRPV1 promotes neurogenic inflammation via neuropeptide signaling. However, drugs designed to directly block TRPV1 may impair its nociceptive roles, essential for tissue preservation. In this work, pain and swelling caused by neurogenic inflammation were mitigated after blocking PLCγ’s activity, modulating TRPV1’s activity without affecting normal chemosensitivity. This suggests that blocking PLCγ could be a new approach for the development of painkillers maintaining the physiological detection of harmful stimuli.
- 1 September 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 329 (3) , C821-C833
PLCγ has a dual role in capsaicin-triggered neurogenic inflammation promoting mechanical hypersensitivity and edema in male mice
When activated, TRPV1 promotes neurogenic inflammation via neuropeptide signaling. However, drugs designed to directly block TRPV1 may impair its nociceptive roles, essential for tissue preservation. In this work, pain and swelling caused by neurogenic inflammation were mitigated after blocking PLCγ’s activity, modulating TRPV1’s activity without affecting normal chemosensitivity. This suggests that blocking PLCγ could be a new approach for the development of painkillers maintaining the physiological detection of harmful stimuli.
- Open Access
- 19 August 2025
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (8) , e70194
Cerebral Dopamine Neurotrophic Factor (CDNF) Acts as a Trophic Factor Promoting Neuritogenesis in the Dorsal Root Ganglia (DRG) Neurons Through Activation of the PI3K Signaling Pathway
The cerebral dopamine neurotrophic factor (CDNF) is a neurotrophic factor extensively studied in the central nervous system because of its neuroprotective effects; however, its role in the peripheral nervous system (PNS) remains less explored. In this study, we used primary dorsal root ganglia (DRG) explants to investigate the neuritogenic potential of exogenous CDNF, as well as its neuroprotective activity under trophic factor deprivation. Our findings demonstrate that CDNF‐mediated neuroprotection remains unaffected by the addition of a Trk (tropomyosin receptor kinase) inhibitor or anti‐nerve growth factor (NGF) antibody, indicating that CDNF's neurotrophic activity is independent of TrkA signaling. Furthermore, CDNF binding to KDEL‐receptor (KDEL‐R) was essential for its protective effect, as the CDNF variant lacking the KDEL‐R binding sequence (CDNF‐ΔKTEL) displayed no significant neuroprotection. Additionally, the simultaneous administration of NGF and CDNF to DRG explants resulted in an additive enhancement of their trophic activities. Notably, both CDNF‐ and NGF‐induced neurotrophic effects were PI3K‐dependent, reinforcing the role of this signaling pathway in their mechanisms of action. Taken together, our findings highlight CDNF's crucial role in the PNS, ensuring that NGF‐independent neurogenesis can occur. This suggests that CDNF could be further explored in conditions where NGF levels are low or where NGF signaling inhibition is desirable, such as in chronic pain management. image
- 19 August 2025
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (8) , e70194
Open AccessCerebral Dopamine Neurotrophic Factor (CDNF) Acts as a Trophic Factor Promoting Neuritogenesis in the Dorsal Root Ganglia (DRG) Neurons Through Activation of the PI3K Signaling Pathway
The cerebral dopamine neurotrophic factor (CDNF) is a neurotrophic factor extensively studied in the central nervous system because of its neuroprotective effects; however, its role in the peripheral nervous system (PNS) remains less explored. In this study, we used primary dorsal root ganglia (DRG) explants to investigate the neuritogenic potential of exogenous CDNF, as well as its neuroprotective activity under trophic factor deprivation. Our findings demonstrate that CDNF‐mediated neuroprotection remains unaffected by the addition of a Trk (tropomyosin receptor kinase) inhibitor or anti‐nerve growth factor (NGF) antibody, indicating that CDNF's neurotrophic activity is independent of TrkA signaling. Furthermore, CDNF binding to KDEL‐receptor (KDEL‐R) was essential for its protective effect, as the CDNF variant lacking the KDEL‐R binding sequence (CDNF‐ΔKTEL) displayed no significant neuroprotection. Additionally, the simultaneous administration of NGF and CDNF to DRG explants resulted in an additive enhancement of their trophic activities. Notably, both CDNF‐ and NGF‐induced neurotrophic effects were PI3K‐dependent, reinforcing the role of this signaling pathway in their mechanisms of action. Taken together, our findings highlight CDNF's crucial role in the PNS, ensuring that NGF‐independent neurogenesis can occur. This suggests that CDNF could be further explored in conditions where NGF levels are low or where NGF signaling inhibition is desirable, such as in chronic pain management. image
- 8 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (857) , eadn4694
Exploring protein-protein interactions for the development of new analgesics
The development of new analgesics has been challenging. Candidate drugs often have limited clinical utility due to side effects that arise because many drug targets are involved in signaling pathways other than pain transduction. Here, we explored the potential of targeting protein-protein interactions (PPIs) that mediate pain signaling as an approach to developing drugs to treat chronic pain. We reviewed the approaches used to identify small molecules and peptide modulators of PPIs and their ability to decrease pain-like behaviors in rodent animal models. We analyzed data from rodent and human sensory nerve tissues to build associated signaling networks and assessed both validated and potential interactions and the structures of the interacting domains that could inform the design of synthetic peptides and small molecules. This resource identifies PPIs that could be explored for the development of new analgesics, particularly between scaffolding proteins and receptors for various growth factors and neurotransmitters, as well as ion channels and other enzymes. Targeting the adaptor function of CBL by blocking interactions between its proline-rich carboxyl-terminal domain and its SH3-domain–containing protein partners, such as GRB2, could disrupt endosomal signaling induced by pain-associated growth factors. This approach would leave intact its E3-ligase functions, which are mediated by other domains and are critical for other cellular functions. This potential of PPI modulators to be more selective may mitigate side effects and improve the clinical management of pain.
- 8 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (857) , eadn4694
Exploring protein-protein interactions for the development of new analgesics
The development of new analgesics has been challenging. Candidate drugs often have limited clinical utility due to side effects that arise because many drug targets are involved in signaling pathways other than pain transduction. Here, we explored the potential of targeting protein-protein interactions (PPIs) that mediate pain signaling as an approach to developing drugs to treat chronic pain. We reviewed the approaches used to identify small molecules and peptide modulators of PPIs and their ability to decrease pain-like behaviors in rodent animal models. We analyzed data from rodent and human sensory nerve tissues to build associated signaling networks and assessed both validated and potential interactions and the structures of the interacting domains that could inform the design of synthetic peptides and small molecules. This resource identifies PPIs that could be explored for the development of new analgesics, particularly between scaffolding proteins and receptors for various growth factors and neurotransmitters, as well as ion channels and other enzymes. Targeting the adaptor function of CBL by blocking interactions between its proline-rich carboxyl-terminal domain and its SH3-domain–containing protein partners, such as GRB2, could disrupt endosomal signaling induced by pain-associated growth factors. This approach would leave intact its E3-ligase functions, which are mediated by other domains and are critical for other cellular functions. This potential of PPI modulators to be more selective may mitigate side effects and improve the clinical management of pain.